Literature DB >> 27584942

Guillain-Barré Syndrome During Ongoing Zika Virus Transmission - Puerto Rico, January 1-July 31, 2016.

Emilio Dirlikov, Chelsea G Major, Marrielle Mayshack, Nicole Medina, Desiree Matos, Kyle R Ryff, Jomil Torres-Aponte, Rebecca Alkis, Jorge Munoz-Jordan, Candimar Colon-Sanchez, Jorge L Salinas, Daniel M Pastula, Myriam Garcia, Marangely Olivero Segarra, Graciela Malave, Dana L Thomas, Gloria M Rodríguez-Vega, Carlos A Luciano, James Sejvar, Tyler M Sharp, Brenda Rivera-Garcia.   

Abstract

Guillain-Barré syndrome (GBS) is a postinfectious autoimmune disorder characterized by bilateral flaccid limb weakness attributable to peripheral nerve damage (1). Increased GBS incidence has been reported in countries with local transmission of Zika virus, a flavivirus transmitted primarily by certain Aedes species mosquitoes (2). In Puerto Rico, three arthropod-borne viruses (arboviruses) are currently circulating: Zika, dengue, and chikungunya. The first locally acquired Zika virus infection in Puerto Rico was reported in December 2015 (3). In February 2016, the Puerto Rico Department of Health (PRDH), with assistance from CDC, implemented the GBS Passive Surveillance System (GBPSS) to identify new cases of suspected GBS (4). Fifty-six suspected cases of GBS with onset of neurologic signs during January 1-July 31, 2016, were identified. Thirty-four (61%) patients had evidence of Zika virus or flavivirus infection; the median age of these patients was 55 years (range = 21-88 years), and 20 (59%) patients were female. These 34 patients were residents of seven of eight PRDH public health regions. All 34 patients were hospitalized and treated with intravenous immunoglobulin G (IVIg), the standard treatment for GBS; 21 (62%) required intensive care unit admission, including 12 (35%) who required endotracheal intubation and mechanical ventilation. One patient died of septic shock after treatment for GBS. Additionally, 26 cases of neurologic conditions other than GBS were reported through GBPSS, including seven (27%) in patients with evidence of Zika virus or flavivirus infection. Residents of and travelers to Puerto Rico and countries with active Zika virus transmission should follow recommendations for prevention of Zika virus infections.* Persons with signs or symptoms consistent with GBS should promptly seek medical attention. Health care providers in areas with ongoing local transmission seeing patients with neurologic illnesses should consider GBS and report suspected cases to public health authorities.

Entities:  

Mesh:

Year:  2016        PMID: 27584942     DOI: 10.15585/mmwr.mm6534e1

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  47 in total

1.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

Review 2.  Animal Models of Zika Virus Infection, Pathogenesis, and Immunity.

Authors:  Thomas E Morrison; Michael S Diamond
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Implementation and Evaluation of Guillain-Barré Syndrome Surveillance in Puerto Rico during the 2016 Zika Virus Epidemic.

Authors:  Chelsea G Major; Emilio Dirlikov; Nicole A Medina; Roberta Lugo-Robles; Desiree Matos; Jorge Muñoz-Jordán; Candimar Colón-Sánchez; Myriam García-Negrón; Marangely Olivero-Segarra; Graciela Malavé-González; Dana L Thomas; Carlos A Luciano; Stephen H Waterman; James Sejvar; Tyler M Sharp; Brenda Rivera-García
Journal:  P R Health Sci J       Date:  2018-12       Impact factor: 0.705

4.  Clinical Features of Guillain-Barré Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016.

Authors:  Emilio Dirlikov; Chelsea G Major; Nicole A Medina; Roberta Lugo-Robles; Desiree Matos; Jorge L Muñoz-Jordan; Candimar Colon-Sanchez; Myriam Garcia; Marangely Olivero-Segarra; Graciela Malave; Gloria M Rodríguez-Vega; Dana L Thomas; Stephen H Waterman; James J Sejvar; Carlos A Luciano; Tyler M Sharp; Brenda Rivera-García
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

5.  Zika in America: The Year in Review.

Authors:  Chris Fellner
Journal:  P T       Date:  2016-12

6.  Acute Zika Virus Infection as a Risk Factor for Guillain-Barré Syndrome in Puerto Rico.

Authors:  Emilio Dirlikov; Nicole A Medina; Chelsea G Major; Jorge L Munoz-Jordan; Carlos A Luciano; Brenda Rivera-Garcia; Tyler M Sharp
Journal:  JAMA       Date:  2017-10-17       Impact factor: 56.272

Review 7.  Zika clinical updates: implications for pediatrics.

Authors:  Kristina Adachi; Karin Nielsen-Saines
Journal:  Curr Opin Pediatr       Date:  2018-02       Impact factor: 2.856

8.  Zika virus outbreak in New Caledonia and Guillain-Barré syndrome: a case-control study.

Authors:  Olivier Simon; Blandine Acket; Carole Forfait; Dominique Girault; Ann-Claire Gourinat; Pauline Millon; Maguy Daures; Jessica Vanhomwegen; Segolene Billot; Antoine Biron; Damien Hoinard; Elodie Descloux; David Guyon; Jean Claude Manuguerra; Sylvie Laumond; Nicolas Molko; Myrielle Dupont-Rouzeyrol
Journal:  J Neurovirol       Date:  2018-03-28       Impact factor: 2.643

9.  Cost projections for implementation of safety interventions to prevent transfusion-transmitted Zika virus infection in the United States.

Authors:  Katherine D Ellingson; Mathew R P Sapiano; Kathryn A Haass; Alexandra A Savinkina; Misha L Baker; Richard A Henry; James J Berger; Matthew J Kuehnert; Sridhar V Basavaraju
Journal:  Transfusion       Date:  2017-06       Impact factor: 3.157

10.  Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model.

Authors:  Justin G Julander; Venkatraman Siddharthan; Joe Evans; Ray Taylor; Kelsey Tolbert; Chad Apuli; Jason Stewart; Preston Collins; Makda Gebre; Skot Neilson; Arnaud Van Wettere; Young-Min Lee; William P Sheridan; John D Morrey; Y S Babu
Journal:  Antiviral Res       Date:  2016-11-10       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.